Wedbush Reiterates Outperform Rating for Aprea Therapeutics (NASDAQ:APRE)

Aprea Therapeutics (NASDAQ:APRE)‘s stock had its “outperform” rating reiterated by research analysts at Wedbush in a research report issued on Tuesday,Benzinga reports. They presently have a $7.00 target price on the stock.

A number of other equities analysts have also recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Wednesday, January 21st. Zacks Research raised Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, February 16th. Finally, HC Wainwright reduced their price target on Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating on the stock in a research report on Tuesday. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $4.10.

Aprea Therapeutics Trading Down 7.7%

Shares of NASDAQ:APRE opened at $0.70 on Tuesday. Aprea Therapeutics has a 1-year low of $0.55 and a 1-year high of $2.22. The stock has a market capitalization of $8.06 million, a P/E ratio of -0.36 and a beta of 1.47. The business has a 50-day moving average price of $0.75 and a two-hundred day moving average price of $1.04.

Aprea Therapeutics (NASDAQ:APRE) last issued its earnings results on Monday, March 16th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.06. The company had revenue of $0.00 million for the quarter. Aprea Therapeutics had a negative net margin of 4,405.59% and a negative return on equity of 96.33%. As a group, equities analysts predict that Aprea Therapeutics will post -2.55 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aprea Therapeutics stock. DRW Securities LLC purchased a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 120,651 shares of the company’s stock, valued at approximately $103,000. DRW Securities LLC owned approximately 1.73% of Aprea Therapeutics at the end of the most recent reporting period. 34.19% of the stock is owned by institutional investors and hedge funds.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.